Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database
In conclusion, incidence of IHD requires closer monitoring in nilotinib-treated patients. More detailed investigations for determining the most useful tool to predict VAE incidence and long-term analysis of therapy-related VAE cases are needed for improving safety during TKI therapy.
Source: Annals of Hematology - Category: Hematology Source Type: research
More News: Cardiology | Chronic Leukemia | Chronic Myeloid Leukaemia | Databases & Libraries | Gleevec | Heart | Heart Disease | Hematology | Japan Health | Leukemia | Nilotinib | Study | Tasigna